Tag: ribose-nucleic acid rna -based therapeutics market forecast.

  • $24.11 Billion Forecast for Ribose-Nucleic Acid (RNA)-Based Therapeutics Market by 2029, Backed by Demand and Innovation

    $24.11 Billion Forecast for Ribose-Nucleic Acid (RNA)-Based Therapeutics Market by 2029, Backed by Demand and Innovation

    Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

    How Fast Is The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Expected to Grow Between 2025 And 2029?

    The market size for ribose-nucleic acid (rna)-based therapeutics has seen significant growth recently. There is projected growth from $15.79 billion in 2024, up to $17.22 billion in 2025, indicating a compound annual growth rate (CAGR) of 9.0%. The expansion during the historic period can be linked to growth in investment and funding, the discovery of RNA interference (RNAi), the clinical victories of antisense oligonucleotides (ASOs), regulatory support and established frameworks, as well as collaborations and partnerships.

    The market size for ribose-nucleic acid (RNA)-based therapeutics is anticipated to experience significant expansion in the coming years, growing to an estimated $24.11 billion in 2029, with a compound annual growth rate (CAGR) of 8.8%. Various factors driving this growth during the forecast period include expanding indications, increased market demand, and adoption, regulatory encouragement, the inclusion of artificial intelligence and machine learning, and new applications for rare diseases. Key trends during this period encompass advanced delivery systems, RNA therapies targeting multiple areas, personalized RNA treatments, regulatory improvements, and market growth and commercialization.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

    What Are the Core Growth Drivers Propelling the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Forward?

    The escalating occurrence of cancer is predicted to fuel the expansion of the ribose-nucleic acid (RNA)-based therapeutics market. Cancer is a disease characterized by the abnormal and uncontrolled growth of cells, which can cause death if not treated. It’s growth is attributed to an aging population, changes in lifestyle, increased exposure to risks, and improved detection techniques. RNA-based therapeutics offer a significant pathway for cancer treatment as they directly target the genetic and molecular causes of cancer. For instance, the Australian Institute of Health and Welfare, a governmental health organization in Australia, reported that approximately 151,000 people were diagnosed with cancer in 2021 (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin), a figure expected to rise to 185,000 by 2030. Consequently, the rising occurence of cancer is propelling the growth of the ribose-nucleic acid (RNA)-based therapeutics market.

    What Segment Types Define the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Structure?

    The ribose-nucleic acid (rna)-based therapeuticsmarket covered in this report is segmented –

    1) By Type: RNA Interference (RNAi); RNA Antisense

    2) By Technology: Enabling Technology; Enabled Technology

    3) By Therapeutic Area: Oncology; Genetic Disorder; Ophthalmology; Hematological Disorders; Acute Hepatic Porphyria (AHP); Other Therapeutic Areas

    4) By End User: Research Institutes; Hospitals And Clinics

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA); MicroRNA (miRNA)

    2) By RNA Antisense: Antisense Oligonucleotides (ASOs); Antisense RNA

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=18454&type=smp

    Which Geographic Areas Hold the Strongest Growth Potential in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Which Emerging Trends that Are Influencing theRibose-Nucleic Acid (RNA)-Based Therapeutics Industry Evolution?

    Leading players in the RNA-based therapeutics market are concentrating on the creation of innovative medicinal solutions such as mRNA-based booster vaccines. The aim is to augment immunization efficiency, adapt to new viral strains, and heighten the longevity of the immunity provided by vaccines. mRNA booster vaccines rely on messenger RNA to stimulate cells into producing a protein that amplifies the body’s defense against specific pathogens. To illustrate, Gennova Biopharmaceuticals Ltd., a pharmaceutical firm from India, introduced GEMCOVAC-OM, the country’s inaugural mRNA booster vaccine aimed at the Omicron variant of COVID-19, in June 2023. This booster becomes necessary in light of the restricted effectiveness of the initial vaccines against Omicron. Employing mRNA technology, GEMCOVAC-OM strengthens immunity and provides superior protection against the continuously mutating virus.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    What Is the Definition of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The ribose-nucleic acid (RNA)-based therapeutics refer to a class of medical treatments that utilize ribose-nucleic acid (RNA) molecules to influence cellular processes, typically by targeting specific genetic sequences. These therapies are designed to treat various conditions, including genetic disorders, cancers, and infectious diseases, by modulating gene expression, protein production, or cellular signaling pathways.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18454

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 310-496-7795

    Europe +44 7882 955267

    Asia & Others +44 7882 955267 & +91 8897263534

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

    Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Outlook 2025: Mapping Growth, Innovation, and Regional Shifts

    Discover trends, market shifts, and competitive outlooks for the ribose-nucleic acid (rna)-based therapeutics industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

    What is the Projected CAGR for the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size from 2025 to 2034?

    The market for ribose-nucleic acid (RNA)-based therapeutics has experienced considerable growth in the past few years. It is projected to increase from $15.79 billion in 2024 to $17.26 billion in 2025, boasting a compound annual growth rate (CAGR) of 9.3%. The development seen historically can be credited to factors such as increased investments and funding, the uncovering of RNA interference (RNAi), favorable outcomes in clinical trials of antisense oligonucleotides (ASOs), supportive regulatory provisions and frameworks, as well as collaborations and partnerships.

    The market for ribose-nucleic acid (RNA)-based therapeutics is projected to witness robust growth in the coming years. The market size is forecasted to reach $24.26 billion in 2029, growing at a compound annual growth rate (CAGR) of 8.9%. Factors contributing to this growth during the forecast period include extended usage of these therapeutics, increasing market demand and acceptance, supportive regulatory frameworks, the incorporation of AI and machine learning, and its emerging usage in treating rare diseases. Foreseen trends during this period involve the development of advanced delivery systems, RNA therapeutics targeting multiple areas, personalized RNA therapies, regulatory breakthroughs, and the commercialization and growth of the market.

    Download a free sample to assess the report’s scope and structure:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

    Which Primay Drivers Are Accelerating Growth in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The escalating incidence of cancer is projected to stimulate the expansion of the ribose-nucleic acid (RNA)-based therapeutics market in the near future. Cancer encompasses a disease state characterized by uncontrolled and abnormal cell growth which can result in death if not treated. Factors such as the aged population, lifestyle alterations, heightened exposure to risks, and superior detection methods contribute to its prevalence. RNA-based therapeutics signify a hopeful prospect for cancer therapy by directly impacting its genetic and molecular underpinnings. For example, the Australian Institute of Health and Welfare, an Australian government health administration, reported in August 2023 that roughly 151,000 individuals were diagnosed with cancer (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021, and this figure is projected to climb to 185,000 by 2030. Consequently, the rising prevalence of cancer is fuelling the growth of the ribose-nucleic acid (RNA)-based therapeutics market.

    What Segment Types Define the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Structure?

    The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –

    1) By Type: RNA Interference (RNAi), RNA Antisense

    2) By Technology: Enabling Technology, Enabled Technology

    3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas

    4) By End User: Research Institutes, Hospitals And Clinics

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)

    2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

    Request customized data on this market:

    https://www.thebusinessresearchcompany.com/customise?id=18454&type=smp

    Which Regions Are Key Players in the Growth of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    What Are the Key Market Trends in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Over the Coming Years?

    Major businesses in the ribose nucleic acid (RNA)-based therapeutics market are concentrating their efforts on creating advanced treatments, such as messenger RNA (mRNA)-based booster vaccines. These innovative medical solutions are intended to boost the potency of immunization, address the rise of new viral strains, and fortify the overall resilience of vaccine-induced immunity. The science behind an mRNA-instigated booster vaccine involves the use of messenger RNA, urging cells to produce a protein that bolsters the body’s defense against specific pathogens. For example, Gennova Biopharmaceuticals Ltd., an enterprise based in India, introduced GEMCOVAC-OM, the nation’s premiere mRNA booster vaccine targeted at the Omicron variant of COVID-19, in June 2023. Given the reduced effectiveness of traditional vaccines against Omicron, this booster plays an indispensable role. Leveraging mRNA technology, GEMCOVAC-OM strengthens immunity and provides superior protection against the mutating virus.

    View the full report here:

    https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    What Is the Definition of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The ribose-nucleic acid (RNA)-based therapeutics refer to a class of medical treatments that utilize ribose-nucleic acid (RNA) molecules to influence cellular processes, typically by targeting specific genetic sequences. These therapies are designed to treat various conditions, including genetic disorders, cancers, and infectious diseases, by modulating gene expression, protein production, or cellular signaling pathways.

    Purchase the full report and get a swift delivery:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18454

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Get in touch with us:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

  • Ribose-Nucleic Acid (RNA)-Based Therapeutics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    Ribose-Nucleic Acid (RNA)-Based Therapeutics Market 2025-2034: Key Highlights, Growth Dynamics, and Emerging Trends

    2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

    What Are the Primary Drivers Supporting the Market Growth of theRibose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The increasing prevalence of cancer is driving the growth of the ribose-nucleic acid (RNA)-based therapeutics market, as RNA therapies offer targeted solutions for complex genetic mechanisms. For example, in August 2023, the Australian Institute of Health and Welfare stated that 151,000 people were diagnosed with cancer in 2021, with projections reaching 185,000 by 2030.

    Get Your Free Sample Report Now – Explore Exclusive Market Insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

    #What is the Projected CAGR for the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size from 2025 to 2034?

    The ribose-nucleic acid (RNA)-based therapeutics market has shown strong growth in recent years. It will increase from $15.79 billion in 2024 to $17.26 billion in 2025, with a compound annual growth rate (CAGR) of 9.3%. This growth is due to increased investment, the discovery of RNA interference (RNAi), clinical successes with antisense oligonucleotides (ASOs), regulatory support, and industry collaborations.

    The ribose-nucleic acid (RNA)-based therapeutics market is projected to reach $24.26 billion by 2029, growing at a CAGR of 8.9%. Contributing factors include expanding indications, market demand, AI and machine learning integration, and emerging applications in rare diseases. Trends include advanced delivery systems, multi-target RNA therapeutics, and commercialization growth.

    You can Directly Purchase the Report Here:

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18454

    What Are the Latest Innovations Influencing theRibose-Nucleic Acid (RNA)-Based Therapeutics Market?

    Major companies in the RNA-based therapeutics market are developing mRNA-based booster vaccines to improve immunization effectiveness. In June 2023, Gennova Biopharmaceuticals Ltd., an India-based pharmaceutical company, launched GEMCOVAC-OM, India’s first mRNA booster vaccine targeting the Omicron variant of COVID-19. This vaccine boosts immunity and offers enhanced protection against the evolving virus.

    Who Are the Major Industry Players Accelerating Growth in theRibose-Nucleic Acid (RNA)-Based Therapeutics Market?

    Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Houston Methodist Hospital, BioNTech, University of Oxford, Alnylam Pharmaceuticals, Sarepta Therapeutics, Flagship Pioneering, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Pharmaceutical Technology, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics

    Order Your Report Now For A Swift Delivery:

    https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    Which Primary Segments of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Are Driving Growth and Industry Transformations?

    The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –

    1) By Type: RNA Interference (RNAi), RNA Antisense

    2) By Technology: Enabling Technology, Enabled Technology

    3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas

    4) By End User: Research Institutes, Hospitals And Clinics

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)

    2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

    Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

    https://www.thebusinessresearchcompany.com/customise?id=18454&type=smp

    Which Regions Are Key Players in the Growth of the #What Are the Primary Drivers Supporting the Market Growth of theRibose-Nucleic Acid (RNA)-Based Therapeutics Market?# Market?

    North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Reports Similar to the Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market 2025, By The Business Research Company:

    Nucleic Acid Based Gene Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

    Nucleic Acid Labeling Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-labeling-global-market-report

    Space Militarization Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/space-militarization-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Analyzing the Future of Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities

    Analyzing the Future of Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities

    Get 20% off on Global Market Reports until March 31st! Use code FY25SAVE at checkout.

    How has the ribose-nucleic acid (rna)-based therapeutics market grown over the years?

    The market size for ribose-nucleic acid (RNA)-based therapeutics has seen significant growth in the past years. It is projected to rise from $15.79 billion in 2024 to $17.26 billion in 2025, recording a compound annual growth rate (CAGR) of 9.3%. The previous growth can be credited to the increase in investments and funding, the breakthrough of RNA interference (RNAi), clinical accomplishments of antisense oligonucleotides (ASOs), regulatory backing and structures, along with collaborations and partnerships.

    What Is the forecasted market size and growth rate for the ribose-nucleic acid (rna)-based therapeutics market?

    The ribose-nucleic acid (RNA)-based therapeutics market size is expected to see strong growth in the next few years. It will grow to $24.26 billion in 2029 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to the expansion of indications, rising market demand and adoption, regulatory support, integration of AI and machine learning, and emerging applications in rare diseases. Major trends in the forecast period include advanced delivery systems, multi-target RNA therapeutics, customized RNA therapies, regulatory advancements, and commercialization and market growth.

    Get your ribose-nucleic acid (rna)-based therapeutics market report here!

    https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    What are the major factors driving growth in the ribose-nucleic acid (rna)-based therapeutics market?

    The escalating incidence of cancer is set to drive the expansion of the ribose-nucleic acid (RNA)-based therapeutics market. Considered a life-threatening condition, cancer is characterized by abnormal and uncontrolled growth of cells. Factors contributing to the prevalence of cancer include an aging demographic, lifestyle shifts, increased exposure to hazards, and improved methods of detection. RNA-based therapeutics are an emerging solution for cancer treatment, directly addressing its genetic and molecular basis. As per data from the Australian Institute of Health and Welfare in August 2023, approximately 151,000 people were confirmed with a cancer diagnosis (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021 in Australia. This number is projected to hit 185,000 by 2030. This rising occurrence of cancer is consequently fueling the growth of the ribose-nucleic acid (RNA)-based therapeutics market.

    What key areas define the segmentation of the global ribose-nucleic acid (rna)-based therapeutics Market?

    The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –

    1) By Type: RNA Interference (RNAi), RNA Antisense

    2) By Technology: Enabling Technology, Enabled Technology

    3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas

    4) By End User: Research Institutes, Hospitals And Clinics

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)

    2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

    Get your free sample now – explore exclusive market insights:

    https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

    Who are the key players steering the development of the ribose-nucleic acid (rna)-based therapeutics market?

    Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Houston Methodist Hospital, BioNTech, University of Oxford, Alnylam Pharmaceuticals, Sarepta Therapeutics, Flagship Pioneering, Ionis Pharmaceuticals, Akcea Therapeutics Inc, Arrowhead Pharmaceuticals, Dicerna Pharmaceuticals, Wave Life Sciences, Pharmaceutical Technology, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, Arbutus Biopharma Corporation, Benitec Biopharma Inc., Olix Pharmaceuticals, Alltrna Inc., Orbital Therapeutics

    What are the key trends shaping the future of the ribose-nucleic acid (rna)-based therapeutics market?

    Key players in the market of ribose nucleic acid (RNA)-based therapeutics are concentrating their efforts in creating innovative medication solutions, such as mRNA (messenger RNA) -based booster vaccines. These efforts are intended to boost the efficiency of immunizations, tackle new viral strains, and enhance the longevity of the immunity provoked by vaccines. mRNA-based booster vaccines work by using messenger RNA to instruct the body’s cells to produce a protein that strengthens the immune defense against a specific infectious agent. For example, in June 2023, Gennova Biopharmaceuticals Ltd., a drug manufacturing company based in India, introduced GEMCOVAC-OM, the country’s first mRNA booster vaccine designed to specifically counter the Omicron variant of COVID-19. This booster is crucial given the reduced effectiveness of original vaccines on Omicron. Through the utilization of mRNA technology, GEMCOVAC-OM heightens the immune response and provides increased protection against the mutating virus.

    Unlock exclusive market insights – purchase your research report now for a swift delivery!

    https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=18454

    What regions are dominating the ribose-nucleic acid (rna)-based therapeutics market growth?

    North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    Browse Through More Similar Reports By The Business Research Company:

    Nucleic Acid Based Gene Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

    Nucleic Acid Labeling Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-labeling-global-market-report

    Space Militarization Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/space-militarization-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

    Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Growth Forecast: Exploring Trends and Opportunities for the Next Decade

    Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

    What Growth Opportunities are Expected to Drive the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market’s CAGR Through 2034?

    The market for ribose-nucleic acid (RNA)-based therapies has seen robust growth in recent years. The market, which is expected to expand from $15.79 billion in 2024 to $17.26 billion in 2025, is projected to witness a compound annual growth rate (CAGR) of 9.3%. The growth experienced in the past years can be credited to an increase in investment and funding, the discovery of RNA interference (RNAi), clinical triumphs of antisense oligonucleotides (ASOs), favorable regulatory frameworks, and a surge in collaborations and partnerships.

    Expectations are high for significant expansion in the ribose-nucleic acid (RNA)-based therapeutics market over the coming years. The projected growth rate is an impressive 8.9% compounded annually, culminating in a market worth $24.26 billion in 2029. This anticipated growth can be linked to factors such as the broadening of indications, accelerating market demand, increased adoption, regulatory backing, the inclusion of artificial intelligence (AI) and machine learning, as well as new applications in the treatment of rare diseases. Key trends for this period include the development of advanced delivery systems, RNA therapeutics targeting multiple areas, personalized RNA treatments, advances in regulations, and the commercial growth and acceleration of the market.

    What Market Dynamics Are Playing a Key Role in Accelerating the Growth of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The escalating occurrence of cancer is anticipated to drive the advancement of the ribose-nucleic acid (RNA)-based therapeutics market in the future. Cancer is a disease marked by the unregulated growth and spread of abnormal cells, potentially fatal if not treated. With an aging population, lifestyle modifications, higher risk exposure, and advanced detection methods, cancer prevalence continues to rise. RNA-based therapeutics provide a beneficial approach for tackling cancer, focusing directly on its genetic and molecular causes. For instance, a report by the Australian Institute of Health and Welfare in August 2023 highlighted that an estimated 151,000 people were diagnosed with cancer (excluding basal cell carcinomas (BCC) and squamous cell carcinomas (SCC) of the skin) in 2021 in Australia. This number is projected to rise to 185,000 in 2030. Hence, the continual increase in cancer cases is propelling the growth of the ribose-nucleic acid (RNA)-based therapeutics market.

    Get Your Free Sample of the Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report Now!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

    What Are the Leading Industry Players Dominating the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    Major companies operating in the ribose-nucleic acid (RNA)-based therapeutics market are:

    • F. Hoffmann-La Roche AG

    • Eli Lilly and Company

    • Novo Nordisk A/S

    • Regeneron Pharmaceuticals

    • Biogen Inc.

    What Are the Latest Trends Leading to Disruption in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    Key players in the ribose nucleic acid (RNA)-focused therapy market are aiming to create innovative therapeutics like messenger RNA (mRNA)-centered booster shots, with the goal to improve immunization efficiency, address new viral mutations, and amplify the overall strength of vaccine-induced immunity. mRNA-based booster vaccines use mRNA to cause cells to produce a protein that heightens the body’s immune resistance to a specific pathogen. For example, in June 2023, Gennova Biopharmaceuticals Ltd., a pharmaceutical firm based in India, unveiled GEMCOVAC-OM, marking India’s debut mRNA booster vaccine designed for the Omicron variant of COVID-19 specifically. This booster has gained importance due to the limited effectiveness of initial vaccines in combating Omicron. By leveraging mRNA science, GEMCOVAC-OM boosts immunity and provides superior defense against the continually mutating virus.

    Get Instant Access to the Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report with Swift Delivery!

    https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    What Major Market Segments Define the Scope and Growth of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –

    1) By Type: RNA Interference (RNAi), RNA Antisense

    2) By Technology: Enabling Technology, Enabled Technology

    3) By Therapeutic Area: Oncology, Genetic Disorder, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas

    4) By End User: Research Institutes, Hospitals And Clinics

    Subsegments:

    1) By RNA Interference (RNAi): Small Interfering RNA (siRNA), MicroRNA (miRNA)

    2) By RNA Antisense: Antisense Oligonucleotides (ASOs), Antisense RNA

    Which Regions Are Significant to the Growth of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2024. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    How Can We Define the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market and Its Key Components?

    The ribose-nucleic acid (RNA)-based therapeutics refer to a class of medical treatments that utilize ribose-nucleic acid (RNA) molecules to influence cellular processes, typically by targeting specific genetic sequences. These therapies are designed to treat various conditions, including genetic disorders, cancers, and infectious diseases, by modulating gene expression, protein production, or cellular signaling pathways.

    Browse Through More Similar Reports By The Business Research Company:

    Nucleic Acid Based Gene Therapy Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

    Nucleic Acid Labeling Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-labeling-global-market-report

    Space Militarization Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/space-militarization-global-market-report

    About The Business Research Company:

    With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • 2024 Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview: Key Insights on Size, Share, and Trends

    2024 Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Overview: Key Insights on Size, Share, and Trends

    Save up to 30% on The Business Research Company’s comprehensive market research reports for a limited time only!

    What is the Anticipated Growth Speed of the Ribose-Nucleic Acid (RNA)-Based TherapeuticsMarket Between 2024 and 2033?

    The ribose-nucleic acid (RNA)-based therapeutics market size has grown strongly in recent years, projected to increase from $14.54 billion in 2023 to $15.79 billion in 2024, with a CAGR of 8.6%. The growth in the historical period can be attributed to increased investment and funding, discoveries in RNA interference (RNAi), successful clinical applications of antisense oligonucleotides (ASOs), regulatory support, and partnerships.

    The RNA-based therapeutics market is anticipated to grow to $22.30 billion by 2028, at a CAGR of 9.0%. Growth drivers include expanded indications, regulatory support, and AI integration in drug development. Emerging trends involve advanced delivery systems, multi-target therapies, and regulatory advancements.

    Which Factors Are Enhancing the Growth of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The increasing occurrence of cancer is expected to accelerate the growth of the ribose-nucleic acid (RNA)-based therapeutics market in the future. Cancer is characterized by the uncontrolled growth and spread of abnormal cells, which can lead to death if not treated. Factors contributing to the prevalence of cancer include an aging population, lifestyle changes, heightened exposure to risk factors, and improved detection techniques. RNA-based therapeutics represent a promising approach to cancer treatment by targeting the genetic and molecular mechanisms associated with the disease.

    Claim Your Free Sample of the Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report Today!

    https://www.thebusinessresearchcompany.com/sample.aspx?id=18454&type=smp

    Which Segments Are Crucial in the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    The ribose-nucleic acid (RNA)-based therapeutics market covered in this report is segmented –

    1) By Type: RNA Interference (RNAi), RNA Antisense
    2) By Technology: Enabling Technology, Enabled Technology
    3) By Therapeutic Area: Oncology, Genetic Disorder, Opthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas
    4) By End User: Research Institutes, Hospitals And Clinics

    What Emerging Trends Are Shaping the Future of the Ribose-Nucleic Acid (RNA)-Based Therapeutics Market?

    Major companies operating in the ribose nucleic acid (RNA)-based therapeutics market are committed to creating innovative medical solutions, such as messenger RNA (mRNA)-based booster vaccines, to improve vaccination effectiveness, tackle emerging viral variants, and boost the durability of vaccine-induced immunity. An mRNA-based booster vaccine utilizes messenger RNA to stimulate cells to produce a protein that enhances the immune response against a specific pathogen. For example, in June 2023, Gennova Biopharmaceuticals Ltd., an Indian pharmaceutical company, introduced GEMCOVAC-OM, India’s first mRNA booster vaccine specifically aimed at the Omicron variant of COVID-19. This booster is crucial due to the limited efficacy of original vaccines against Omicron. By employing mRNA technology, GEMCOVAC-OM enhances immunity and provides better protection against the evolving virus.

    Order Now for Fast Delivery of Your Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report!

    https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    What Regions Are At the Forefront of Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Expansion?

    North America was the largest region in the ribose-nucleic acid (RNA)-based therapeutics market in 2023. The regions covered in the ribose-nucleic acid (RNA)-based therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

    The Ribose-Nucleic Acid (RNA)-Based Therapeutics Global Market Report 2024 offers a comprehensive overview of the audio equipment market, covering historical data from 2010 to 2021 and providing a ten-year forecast from 2023 to 2032. This report examines the size of the ribose-nucleic acid (rna)-based therapeutics market, its market share, and analyzes key competitors along with their market positions.

    The Table Of Content For The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Include

    1. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Executive Summary
    2. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Segments
    3. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Size And Template Market Growth Rate
    4.  Key Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Trends
    5. Major Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Drivers
    ……
    25. Key Mergers And Acquisitions In The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market
    26. Top Ribose-Nucleic Acid (RNA)-Based Therapeutics Companies
    27. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Opportunities And Strategies
    28. Ribose-Nucleic Acid (RNA)-Based Therapeutics Market, Conclusions And Recommendations
    29. Appendix

    Discover Related Reports by The Business Research Company:

    Nucleic Acid Based Gene Therapy Market Size, Share, Analysis and Forecast 2033

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-based-gene-therapy-global-market-report

    Nucleic Acid Isolation & Purification Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/nucleic-acid-isolation-and-purification-global-market-report

    Automated Nucleic Acid Extraction Devices Global Market Report 2024

    https://www.thebusinessresearchcompany.com/report/automated-nucleic-acid-extraction-devices-global-market-report

    Learn More About The Business Research Company

    The Business Research Company has published over 15000+ reports in 27 industries, spanning 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

    Contact us at:

    The Business Research Company: https://www.thebusinessresearchcompany.com/

    Americas +1 3156230293

    Asia +44 2071930708

    Europe +44 2071930708

    Email us at info@tbrc.info

    Follow us on:

    LinkedIn: https://in.linkedin.com/company/the-business-research-company

    YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

    Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

    Found this article helpful? Share it on:

  • Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2024: Market Size, Drivers, And Trends

    Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2024: Market Size, Drivers, And Trends

    The Business Research Company’s global market reports are now updated with the latest market sizing information for the year 2024 and forecasted to 2033

    The ribose-nucleic acid (RNA)-based therapeutics market has experienced significant growth in recent years. This blog provides insights into the market’s size, key trends, growth drivers, and major players, with a focus on the future potential of RNA-based therapeutics.

    Market Growth Overview

    • Strong Growth: The market size of RNA-based therapeutics increased from $14.54 billion in 2023 to $15.79 billion in 2024 at a CAGR of 8.6%.
    • Future Projections: The market is expected to reach $22.30 billion by 2028, growing at a CAGR of 9.0%.
    • Historic Growth Factors: Increased investments, discovery of RNA interference (RNAi), clinical successes of antisense oligonucleotides (ASOs), and regulatory support fueled the market’s growth.

    Key Drivers of Market Expansion

    • Rising Cancer Prevalence: The increasing global prevalence of cancer is a major driver. Cancer cases are expected to rise from 151,000 in 2021 to 185,000 by 2030 in Australia alone, according to the Australian Institute of Health and Welfare.
    • RNA Therapeutics in Cancer Treatment: RNA-based therapies target the genetic mechanisms of cancer, offering promising treatment options that can address the growing number of cases.
    • Regulatory Support: Governments and regulatory bodies have offered frameworks and guidelines to fast-track RNA-based therapeutic development.

    View More On The Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2024 – https://www.thebusinessresearchcompany.com/report/ribose-nucleic-acid-rna-based-therapeutics-global-market-report

    Emerging Trends in RNA-Based Therapeutics

    • Advanced Delivery Systems: Innovations in delivery technologies are enhancing the efficacy of RNA-based drugs.
    • Multi-Target RNA Therapeutics: RNA therapies are evolving to target multiple disease mechanisms, broadening their applicability.
    • Customized RNA Therapies: Personalized RNA treatments are emerging as a major trend, allowing for tailored treatment approaches.
    • AI and Machine Learning Integration: AI is being used to optimize drug discovery and design, accelerating the development of RNA-based therapies.
    • Regulatory Advancements: Ongoing improvements in regulatory pathways are facilitating faster approvals and commercialization of RNA-based drugs.

    Key Market Segments

    • By Type: RNA Interference (RNAi), RNA Antisense
    • By Technology: Enabling Technology, Enabled Technology
    • By Therapeutic Area: Oncology, Genetic Disorders, Ophthalmology, Hematological Disorders, Acute Hepatic Porphyria (AHP), Other Therapeutic Areas
    • By End User: Research Institutes, Hospitals, and Clinics

    The Role of mRNA-Based Vaccines

    • mRNA Booster Vaccines: Major companies are focused on developing mRNA-based vaccines to address new viral variants. These vaccines use messenger RNA to enhance the body’s immune response.
    • Example of Innovation: In June 2023, Gennova Biopharmaceuticals launched GEMCOVAC-OM, India’s first mRNA booster vaccine targeting the Omicron variant of COVID-19. This vaccine is designed to enhance immunity against emerging viral variants, showcasing the potential of mRNA technology.

    Leading Players in the Market
    Key players in the RNA-based therapeutics market include:

    • Pharmaceutical Companies: F. Hoffmann-La Roche AG, Eli Lilly and Company, Novo Nordisk A/S, Regeneron Pharmaceuticals, Biogen Inc., Alnylam Pharmaceuticals, Sarepta Therapeutics, and BioNTech.
    • Biotech Firms: Akcea Therapeutics Inc., Dicerna Pharmaceuticals, Quark Pharmaceuticals, Tekmira Pharmaceuticals, ReCode Therapeutics, and Benitec Biopharma Inc.
    • Research Institutions: University of Oxford, Houston Methodist Hospital

    Regional Insights

    • North America Dominates: North America was the largest region in the RNA-based therapeutics market in 2023.
    • Global Expansion: The regions covered in the RNA-based therapeutics market include Asia-Pacific, Western Europe, Eastern Europe, South America, the Middle East, and Africa, each poised to see market growth.

    Conclusion
    The RNA-based therapeutics market is on a strong growth trajectory, driven by advancements in technology, regulatory support, and increasing applications, particularly in cancer treatment. With continued innovation in RNA delivery systems and the integration of AI, the market is poised to expand further, offering promising therapeutic solutions for various diseases.

    Request A Sample Of The Global Ribose-Nucleic Acid (RNA)-Based Therapeutics Market Report 2024:
    https://www.thebusinessresearchcompany.com/sample_request?id=18454&type=smp